Codexis discovers, develops and sells enzymes and other proteins to its clients. Co.'s business segments are: Performance Enzymes, which uses its technology to develop enzymes for customers using next generation sequencing and polymerase chain reaction for in vitro molecular diagnostic and molecular biology research applications, as well DNA/RNA synthesis and health monitoring applications; and Novel Biotherapeutics, which discovers, improves, and/or develops biotherapeutic drug candidates, including CDX-6114 for the potential treatment of hyperphenylalaninemia. Co.'s products include biocatalysts, chemical intermediates and Codex® biocatalyst panels and kits. We show 58 historical shares outstanding datapoints in our CDXS shares outstanding history coverage, used to compute CDXS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CDXS market cap history over the course of time is important for investors
interested in comparing CDXS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CDXS versus a peer is one thing; comparing
CDXS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CDXS can fluctuate over the course of history.
With this page we aim to empower investors researching CDXS by allowing them to research the CDXS market cap history. |
Free CDXS Email Alerts:
Video: The Importance of Market Cap
